A5030718236- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Herpesvirus Infections and Treatments
- Oral microbiology and periodontitis research
- Cytomegalovirus and herpesvirus research
- Cancer-related Molecular Pathways
- Protease and Inhibitor Mechanisms
- Social Sciences and Policies
- Bladder and Urothelial Cancer Treatments
- Cybersecurity and Cyber Warfare Studies
- Cardiovascular Conditions and Treatments
- Immunodeficiency and Autoimmune Disorders
- Blood Coagulation and Thrombosis Mechanisms
- Metallic Glasses and Amorphous Alloys
- Blood transfusion and management
- Airway Management and Intubation Techniques
- Sleep and Work-Related Fatigue
- Scientific Computing and Data Management
- Composite Material Mechanics
- Poxvirus research and outbreaks
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
Washington University in St. Louis
2022-2024
Health Outcomes Solutions (United States)
2024
Centro di Riferimento Oncologico
2018-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2018-2023
Kennedy Krieger Institute
2023
Virginia Tech
2022
Roswell Park Comprehensive Cancer Center
2019
Brooke Army Medical Center
2015-2016
Saint Louis University
2015
Johns Hopkins University
2010
Abstract Purpose: In chronic lymphocytic leukemia (CLL), TP53 mutations are associated with reduced survival and resistance to standard chemoimmunotherapy (CIT). Nevertheless, the clinical impact of subclonal below 10% 15% variant allele frequency (VAF) remains unclear. Experimental Design: Using a training/validation approach, we retrospectively analyzed biological features above (high-VAF) or (low-VAF) previously reported 10.0% VAF threshold, as determined by deep next-generation...
Hemorrhage is the leading cause of preventable trauma-related mortality and frequently aggravated by acute traumatic coagulopathy (ATC). Viscoelastic tests such as rotational thromboelastometry (ROTEM) may improve identification management ATC. This study aimed to prospectively evaluate changes in ROTEM among combat casualties during first 24 hours compare capabilities our conventional clotting assay (international normalized ratio [INR], >1.2) a proposed integrated model (INR >1.2 with...
We present a laboratory-based prognostic calculator (designated CRO score) to risk stratify treatment-free survival in early stage (Rai 0) chronic lymphocytic leukemia (CLL) developed using training-validation model series of 1,879 cases from Italy, the United Kingdom and States. By means regression analysis, we identified five variables with weighting as follows: deletion short arm chromosome 17 unmutated immunoglobulin heavy chain gene status, 2 points; long 11, trisomy 12, white blood...
Introduction: There is paucity of literature about the validation American College Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) surgical risk calculator for prediction outcomes after robot-assisted radical cystectomy (RARC). We sought to evaluate accuracy ACS NSQIP in patients who underwent RARC at our institute. Methods: retrospectively reviewed prospectively maintained database between 2005 and 2017. Accuracy was assessed, by comparing rate actual complication events...
Background and Objective: Endothelial cells have a substantial role in maintaining vascular homeostasis, their dysregulation can contribute to the development of pathology. The plasminogen activators inhibitors may, arguably, be single most important proteolytic system endothelium for maintenance by controlling activation other cascades that impact on clotting, hemodynamics, angiogenesis character wall. In chronic periodontal disease, significant changes microvasculature occur association...
6023 Background: Drugs bound to albumin selectively target cancer cells with upregulated macropinocytosis, an endocytic nutrient-scavenging process driven by constitutive hyper-activation of the EGFR, RAS, PIK3CA and Syndecan1 signaling pathways that frequently occur in HNSCC. nab-paclitaxel is active drug HNSCC has immunologic effects can prime immune response PD-1 inhibitors, potentially reversing resistance these agents. These include decreased TREGs, increased pro-inflammatory...
Outcomes in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who undergo autologous stem cell transplant (auto-SCT) are poor. Blinatumomab is a CD3/CD19 bispecific T-cell engager that directs cytotoxic T cells to CD19+ cells. Here, we performed pilot study of blinatumomab consolidation after auto-SCT for 14 DLBCL or transformed follicular lymphoma. All underwent standard-of-care carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning followed by 1 cycle (4 weeks...
Background and Objective: The plasminogen activating system is a protease/inhibitor central to extracellular matrix remodeling with suggested role in periodontal disease pathology. A few studies have reported polymorphisms the genes of activator inhibitors be associated severity. Two gene – Bam HI restriction fragment length polymorphism urokinase ( uPA ) Hin dIII inhibitor type 1 PAI‐1 been conditions having vascular component, our objective was assess association these alveolar bone loss...
6022 Background: EZH2 is the catalytic subunit of PRC2, which catalyzes H3K27me3 target gene promotors and silences transcription several cancer-related genes. overexpression common in HNSCC correlated with methylation tumor suppressor siRNA downregulated mRNA protein reduced colony formation an EZH2-expressing cell line. inhibitors decreased HPV + - lines. Tazemetostat, inhibitor, upregulated expression HLA class I molecules anti-PD-1-resistant lines mouse models, increased antigen-specific...
Abstract Preclinical data support investigation of selective CDK4/6 inhibition as a therapeutic strategy for human papillomavirus (HPV)–unrelated head and neck squamous cell carcinoma (HNSCC). Phase 1 clinical trials established the feasibility combining palbociclib with cetuximab in patients recurrent or metastatic HNSCC. Nonrandomized phase II showed that plus resulted efficacy outcomes better than biomarker-unselected, platinum-resistant cetuximab-resistant, HPV-unrelated A double-blind,...
TPS3189 Background: Arginine is essential to neoplastic growth and development, yet many cancer cells do not express argininosuccinate synthetase (ASS1), an enzyme necessary produce arginine. ADI-PEG 20 a microbial that degrades arginine causing auxotrophy in are ASS1 negative. Preclinical data suggests combination with docetaxel (D), resulted increased expression of hENT, the transporter for gemcitabine (G) as well upregulation dCK trap G inside cells. A phase II trial 20, D was shown be...
TPS6109 Background: Patients with locally advanced HPV+ OPSCC have a favorable prognosis; however, 10-40% will experience disease recurrence after curative-intent therapy (CIT). 80-90% of cases are caused by HPV genotype 16. HPV16 E7 is promising target as there little variation among isolates and high epitope affinities for HLA--A*0201 been identified. the most common class I allele in USA, expressed 40-50% people European descent. We aim to lower rate these patients activating tumor...
6016 Background: The homologous recombination deficiency (HRD) phenotype is common in HNSCC and due to mutation promoter hypermethylation of DNA repair genes ( BRCA1, BRCA2, ATR, ATM, FANC) PTEN. In pre-clinical models HNSCC, HRD sensitizes tumor PARP inhibition additive antitumor activity combination with platinum agents. inhibitors also activate the STING pathway upregulate PD-L1 expression, resulting synergistic when given PD-1 inhibitors. Olaparib a highly selective inhibitor that has...
6015 Background: Cell cycle deregulation is ubiquitous in HNSCC. In HPV-negative disease, the most common genomic alteration of cell-cycling included CDKN2A deletions (57%), mutations (27%) or hypermethylation (12%). Selective CDK4/6 inhibition arrested cell cycling and inhibited tumor growth cell-line xenograft models HNSCC, alterations were predictive response. An exploratory analysis a double-blind, randomized, phase 2 trial patients with recurrent/metastatic HNSCC showed that associated...
TPS6103 Background: Cell cycle deregulation is ubiquitous in HNSCC. In HPV-negative HNSCC, the most common genomic cell-cycling alteration involves CDKN2A, which results loss of p16 expression, hyper-activation CDK4/6-cyclin D1, unrestrained cell cycling and tumor progression. The modest antitumor activity cetuximab HNSCC may be due to unregulated events downstream EGFR. cell-line, xenograft, PDX models selective CDK4/6 inhibition arrested inhibited growth. CDKN2A alterations were predictive...